Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas
Antineoplastic Combined Chemotherapy Protocols
Soft Tissue Neoplasms
Fixed-dose-rate gemcitabine and docetaxel is a reasonable treatment option for patients with advanced soft-tissue sarcoma. The regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma. The role of adjuvant gemcitabine-docetaxel in completely resected, uterine-limited, high-grade leiomyosarcoma is under investigation.